Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy
- 332 Downloads
Previous studies have reported activation of inflammatory cytokines in seizures, but clinical characteristics of epilepsy associated with cytokine activation have not been well established. In this study, serum levels of interleukin-6 (IL-6) and interleukin-1 receptor antagonist (IL-1RA) were measured, and clinical characteristics of epilepsy were assessed in 86 well-evaluated patients with refractory focal epilepsy and in 5 patients with controlled focal epilepsy. Epilepsy was evaluated based on patient histories, electroclinical findings, and high-resolution brain MRI scans. Sixty-three healthy blood donors served as controls. IL-6 concentrations were chronically increased in epilepsy patients (11%) compared with healthy controls (0%) (P = 0.007). Increased levels of IL-6 were more prevalent in patients with temporal lobe epilepsy (TLE) compared to patients with extra-TLE (P = 0.028). Also the mean and the median serum levels of IL-6 were higher in patients with TLE than in patients with extra-TLE (P = 0.042). Concentrations of IL-1RA were not significantly different in patients compared with controls. Indicated by increased levels of IL-6 in TLE, epilepsy type is important in determining chronic overproduction of cytokines in refractory focal epilepsy. The results may reflect a chronic immunological process in the brain in patients with refractory epilepsy.
KeywordsRefractory focal epilepsy Cytokines Epilepsy type
We thank Raija Paalavuo for her excellent assistance with cytokine measurements, and Dr. Aarne Ylinen, Head of Käpylä Rehabilitation Centre, Helsinki, for his comments on the manuscript.
- 4.Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, De Luigi A, De Simoni MG, Sperk G, Andell-Jonsson S, Lundkvist J, Iverfeldt K, Bartfai T (2000) Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci USA 10:11534–11539CrossRefGoogle Scholar
- 10.Woiciechowsky C, Schöning B, Daberkow N, Asche K, Stoltenburg G, Lanksch WR, Volk HD (1999) Brain-IL-1beta induces local inflammation but systemic anti-inflammatory response through stimulation of both hypothalamic–pituitary-adrenal axis and sympathetic nervous system. Brain Res 23:563–571CrossRefGoogle Scholar
- 17.Peltola J, Kulmala P, Isojärvi J, Saiz A, Latvala K, Palmio J, Savola K, Knip M, Keränen T, Graus F (2000) Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 12:46–50Google Scholar
- 19.Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127:701–712CrossRefPubMedGoogle Scholar
- 29.Lim C, Alexander MP, LaFleche G, Schnyer DM, Verfaellie M (2004) The neurological and cognitive sequelae of cardiac arrest. Neurology 23:1774–1778Google Scholar
- 37.McGeer PL, Rogers J, McGeer EG (2006) Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimer′s Dis 9:271–276Google Scholar